 |
- Exploring the Systems of Care in ASCVD Management, a healthcare industry panel discussion from the NLA
|
 |
- First Human Trial of a Loading Dose of Icosapent Ethyl in Patients with COVID-19: Primary Results of the VASCEPA COVID-19 CardioLink-9 Randomized Trial, presented by Deepak L Bhatt, MD, MPH
- Reductions in lipoprotein(a) with inclisiran– Analysis from ORION-10 and ORION-11, presented by Frederick Raal, FRCP, FCP(SA), Cert Endo, MMED, PhD
- EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (Encore Presentation), presented by Michael Miller, MD, FACC, FAHA
|
 |
- CRISPR-Cas9 genome editing for treatment of atherogenic dyslipidemia
- Update on Clinical Trials: How Will This Affect Practice in the Future?
- Resistant Hypertension: A Practical Approach to the Guidelines
- These activity highlights supported by Alexion Pharmaceuticals, Inc.
|
 |
- Bariatric Surgery: What a Lipidologist Needs to Know
- Lipodystrophy
- Cream of Tomato Soup" Blood: What's the Skinny on FCS and Other Chylomicronemic States?
- Cholesterol Screening in Children and Young Adults. Where are we going?
|
 |
- Noninvasive Imaging for Atherosclerosis Regression
- Identification of Rare Triglyceride Disorders
- Therapeutic Options for Triglyceride Lowering
- Is Lower Better for LDL or is there a “Sweet Spot”
|
 |
- Uncommon Dyslipidemias with Common Presentations
- Human Genetics and CV Risk Assessment
- Lipoprotein(a) as a Cause of Cardioborbobbvascular Disease
- Management of FH in Pregnancy: An art or an oxymoron?
- Gut Microbiota and Atherothrombotic Heart Disease
- Updates to the 2016 NLA Annual Summary - Secrets Revealed
|
 |
- PCSK9 Inhibitors: Practical Aspects of their use in Patients with Familial Hypercholesterolemia
- Key Clinical Lipidology Publications: 2015-16
- Should PCSK9 Inhibitors be Used in Statin Intolerant Patients?
- PCSK9 Inhibitors: Impact on the Management of LDL Apheresis Candidates and LDL Apheresis Patients
|
 |
- Keeping NLA Members Up-to-Date: Key Articles for the 2016 NLA Annual Summary
- NLA Recommendations for Patient-Centered Management of Dyslipidemia- Part 2
- Statin Intolerance as a Barrier to Atherosclerotic Disease Risk Reduction
|
 |
- NLA Recommendations for Management of Special Populations
- New Evidence & Outcomes: Information Lipidologists Need to Know
- New Evidence & Outcomes: Information Lipidologists Need to Know
- Hypertension: How New Guidelines Should Change Your Practice?
- Case Discussions: Treatment Strategies for High Risk Populations
- South Asian Ethnicity - Management and Associated Risk
|
 |
- Two Different Prevention Approaches Two Different Perspectives
- Inflammation, Risk Prediction, and the Prevention of ASCVD
- Clinical Management of Hypertriglyceridemia: State of the Art 2015
- ApoB in Risk Assessment and the Diagnosis and Treatment of the Atherogenic Dyslipoproteinemias
|
 |
- NLA Recommendations for Patient-Centered Management of Dyslipidemia
- Data Supported Evidence for Differences in the ACC/AHA Guidelines and NLA Recommendations for Dyslipidemia Management
- Current & Future Triglyceride Pharmaceuticals
- Hypertriglyceridemia Awareness Survey Results
- Nutrition in Hypertriglyceridemia: Choosing the 'Right' Diet for the 'Right' Patient
- Are Triglycerides a Cardiovascular Risk Factor?
|
 |
- 2014 NLA Statin Safety Task Force
- Effect of Statins on Exercise Performance
- A Short History of PCSK9 - From Discovery to Clinical Trials
- Familial Hypercholesterolemia & Pregnancy
- Understanding US Lipid Guidelines 2013
- IAS Position Paper: Global Recommendations for the Management of Dyslipidemia
|
 |
- Keynote: Guidelines for Lipid Management in 2014
- HDL: State of the Lipoprotein
- Omega 3's and Cardiovascular Disease: High versus Low Dose?
|
 |
- Keynote: HDL Review
- Is Raising HDL Dead or Not?
- Genetics of Familial Hypercholesterolemia
- Genetic Testing - Where are we? Nuts & Bolts of Testing
- Cardiometabolic Consequences of Sitting Time
|
 |
- Promise and Pitfalls of Lifetime Risk Assessment for CVD
- NLA HDL Consensus Statement
- DHA and the Brain: Is it an Essential Nutrient?
- Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
- HPS2-THRIVE
- Personalize Antiplatelet Therapy: State of the Art
- Obesity, Adiposity, and Dyslipidemia: A Consensus Statement from the NLA
- Statin Therapy and Incident Diabetes
- Preparing for Guidelines in 2013
|
 |
- Gender Differences in CVD Risk Management
- Untangling the "Heavy" Cardiovascular Burden of Obesity
- Pregnancy and Dyslipidemia: A Window of Future Health
- Understanding and Communicating Risk
|
 |
- The Need to Reduce Sodium in the U.S. Diet
- Debate Part 1 - Is High-fructose Corn Syrup a Problem?
- Debate Part 2 - Is High-fructose Corn Syrup a Problem?
- Statin Therapy and New Onset Diabetes Mellitus
- Clinical Decision Making: Taking COURAGE to AIM-HIGH
- The High-Risk Plaque (HRP) Initiative
- Debate Part 1 - EPA and DHA
- Debate Part 2 - EPA and DHA
- Characterizing Cardiovascular Risk in Hispanic Americans
|
 |
- The Problem Patient: Managing Statin Myalgias
- Beyond Diet Wars: Practical Advice for Your Patient
- NonHDL and Diabetic Dyslipidemia: A Clinician's Perspective
- HDL-C: Should We Continue to AIM-HIGH
|
 |
- Clinical Trial Updates Impacting Your Practice
- The Impact of Prescription Switching on LDL-C Goal Attainment
- Genetic Susceptibility to Statin-Induced Myopathy
- The Case For A Low-Fat/Good Carbohydrate Diet
- HDL Functionality: How Do We Measure It and Is It Relevant
- What Do Simple Genetics Tell Us About Complex Diseases?
- Common Etiologies of Hypertriglyceridemia
- Novel Therapies on the Horizon
- CKD in the Light of The SHARP Trial
|
